-
1
-
-
84971619896
-
ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
-
[1] Roffi, M., Patrono, C., Collet, J.P., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 3 (2016), 267–315.
-
(2016)
Eur Heart J
, vol.3
, pp. 267-315
-
-
Roffi, M.1
Patrono, C.2
Collet, J.P.3
-
2
-
-
84866732231
-
ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
-
[2] Steg, P.G., James, S.K., Atar, D., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33 (2012), 2569–2619.
-
(2012)
Eur Heart J
, vol.33
, pp. 2569-2619
-
-
Steg, P.G.1
James, S.K.2
Atar, D.3
-
3
-
-
84920278525
-
AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines
-
[3] Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 130 (2014), e344–e426.
-
(2014)
Circulation
, vol.130
, pp. e344-e426
-
-
Amsterdam, E.A.1
Wenger, N.K.2
Brindis, R.G.3
-
4
-
-
84872698656
-
ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines
-
[4] O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 61 (2013), e78–e140.
-
(2013)
J Am Coll Cardiol
, vol.61
, pp. e78-e140
-
-
O'Gara, P.T.1
Kushner, F.G.2
Ascheim, D.D.3
-
5
-
-
49749120012
-
Prevalence, predictors, and impact of conservative medical management for patients with non–ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease
-
[5] Chan, M.Y., Mahaffey, K.W., Sun, L.J., et al. Prevalence, predictors, and impact of conservative medical management for patients with non–ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. JACC Cardiovasc Interv 1 (2008), 369–378.
-
(2008)
JACC Cardiovasc Interv
, vol.1
, pp. 369-378
-
-
Chan, M.Y.1
Mahaffey, K.W.2
Sun, L.J.3
-
6
-
-
67650556158
-
The paradoxical use of cardiac catheterization in patients with non–ST-elevation acute coronary syndromes: lessons from the can rapid stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) quality improvement initiative
-
[6] Cohen, M.G., Filby, S.J., et al. The paradoxical use of cardiac catheterization in patients with non–ST-elevation acute coronary syndromes: lessons from the can rapid stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) quality improvement initiative. Am Heart J 158 (2009), 263–270.
-
(2009)
Am Heart J
, vol.158
, pp. 263-270
-
-
Cohen, M.G.1
Filby, S.J.2
-
7
-
-
80052162121
-
Apixaban with antiplatelet therapy after acute coronary syndrome
-
[7] Alexander, J.H., Lopes, R.D., James, S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365 (2011), 699–708.
-
(2011)
N Engl J Med
, vol.365
, pp. 699-708
-
-
Alexander, J.H.1
Lopes, R.D.2
James, S.3
-
8
-
-
80052232522
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
-
[8] Oldgren, J., Budaj, A., Granger, C.B., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32 (2011), 2781–2789.
-
(2011)
Eur Heart J
, vol.32
, pp. 2781-2789
-
-
Oldgren, J.1
Budaj, A.2
Granger, C.B.3
-
9
-
-
80054733922
-
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor XA inhibitor darexaban (YM150) following acute coronary syndrome
-
[9] Steg, P.G., Mehta, S.R., Jukema, J.W., et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor XA inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 32 (2011), 2541–2554.
-
(2011)
Eur Heart J
, vol.32
, pp. 2541-2554
-
-
Steg, P.G.1
Mehta, S.R.2
Jukema, J.W.3
-
10
-
-
83655177669
-
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
-
[10] Tricoci, P., Huang, Z., Held, C., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366 (2012), 20–33.
-
(2012)
N Engl J Med
, vol.366
, pp. 20-33
-
-
Tricoci, P.1
Huang, Z.2
Held, C.3
-
11
-
-
67649562905
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
-
[11] Mega, J.L., Braunwald, E., Mohanavelu, S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374 (2009), 29–38.
-
(2009)
Lancet
, vol.374
, pp. 29-38
-
-
Mega, J.L.1
Braunwald, E.2
Mohanavelu, S.3
-
12
-
-
84862907587
-
Rivaroxaban in patients with a recent acute coronary syndrome
-
[12] Mega, J.L., Braunwald, E., Wiviott, S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
-
(2012)
N Engl J Med
, vol.366
, pp. 9-19
-
-
Mega, J.L.1
Braunwald, E.2
Wiviott, S.D.3
-
13
-
-
84913619061
-
ESC/EACTS guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
-
[13] Windecker, S., Kolh, P., Alfonso, F., et al. ESC/EACTS guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 35 (2014), 2541–2619.
-
(2014)
Eur Heart J
, vol.35
, pp. 2541-2619
-
-
Windecker, S.1
Kolh, P.2
Alfonso, F.3
-
14
-
-
0015956225
-
A randomized controlled trial of acetyl salicyclic acid in the secondary prevention of mortality from myocardial infarction
-
[14] Elwood, P.C., Cochrane, A.L., Burr, M.L., et al. A randomized controlled trial of acetyl salicyclic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1 (1974), 436–440.
-
(1974)
Br Med J
, vol.1
, pp. 436-440
-
-
Elwood, P.C.1
Cochrane, A.L.2
Burr, M.L.3
-
15
-
-
0023805341
-
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
-
[15] Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 332 (1988), 349–360.
-
(1988)
Lancet
, vol.332
, pp. 349-360
-
-
-
16
-
-
0025090942
-
Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
-
[16] Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990), 827–830.
-
(1990)
Lancet
, vol.336
, pp. 827-830
-
-
-
17
-
-
0026042937
-
Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization
-
[17] Wallentin, L.C., Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 18 (1991), 1587–1593.
-
(1991)
J Am Coll Cardiol
, vol.18
, pp. 1587-1593
-
-
Wallentin, L.C.1
-
18
-
-
0032481092
-
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
-
[18] Leon, M.B., Baim, D.S., Popma, J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998), 1665–1671.
-
(1998)
N Engl J Med
, vol.339
, pp. 1665-1671
-
-
Leon, M.B.1
Baim, D.S.2
Popma, J.J.3
-
19
-
-
0035899289
-
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
-
[19] Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
-
(2001)
N Engl J Med
, vol.345
, pp. 494-502
-
-
-
20
-
-
3242770664
-
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial
-
[20] Diener, H.C., Bogousslavsky, J., Brass, L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004), 331–337.
-
(2004)
Lancet
, vol.364
, pp. 331-337
-
-
Diener, H.C.1
Bogousslavsky, J.2
Brass, L.M.3
-
21
-
-
73949157474
-
Platelet thrombin receptor antagonism and atherothrombosis
-
[21] Angiolillo, D.J., Capodanno, D., Goto, S., Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 31 (2010), 17–28.
-
(2010)
Eur Heart J
, vol.31
, pp. 17-28
-
-
Angiolillo, D.J.1
Capodanno, D.2
Goto, S.3
-
22
-
-
0034068625
-
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
-
[22] Sugidachi, A., Asai, F., Ogawa, T., et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 129 (2000), 1439–1446.
-
(2000)
Br J Pharmacol
, vol.129
, pp. 1439-1446
-
-
Sugidachi, A.1
Asai, F.2
Ogawa, T.3
-
23
-
-
0141924393
-
Coagulation activation and long-term outcome in acute coronary syndromes
-
[23] Ardissino, D., Merlini, P.A., Bauer, K.A., et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 102 (2003), 2731–2735.
-
(2003)
Blood
, vol.102
, pp. 2731-2735
-
-
Ardissino, D.1
Merlini, P.A.2
Bauer, K.A.3
-
24
-
-
0028356326
-
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
-
[24] Merlini, P.A., Bauer, K.A., Oltrona, L., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90 (1994), 61–68.
-
(1994)
Circulation
, vol.90
, pp. 61-68
-
-
Merlini, P.A.1
Bauer, K.A.2
Oltrona, L.3
-
25
-
-
78149487486
-
Effect of rivaroxaban on markers of coagulation in patients with acute coronary syndromes: an ATLAS ACS-TIMI 46 substudy
-
[25] Gibson, C.M., Mega, J.L., Jennings, L.H., et al. Effect of rivaroxaban on markers of coagulation in patients with acute coronary syndromes: an ATLAS ACS-TIMI 46 substudy. Circulation, 120, 2009, S1035.
-
(2009)
Circulation
, vol.120
, pp. S1035
-
-
Gibson, C.M.1
Mega, J.L.2
Jennings, L.H.3
-
26
-
-
84943648606
-
Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies
-
[26] Perzborn, E., Heitmeier, S., Laux, V., Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 20 (2015), 554–562.
-
(2015)
J Cardiovasc Pharmacol Ther
, vol.20
, pp. 554-562
-
-
Perzborn, E.1
Heitmeier, S.2
Laux, V.3
-
27
-
-
84875720372
-
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
-
[27] Dewilde, W.J., Oirbans, T., Verheugt, F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
-
(2013)
Lancet
, vol.381
, pp. 1107-1115
-
-
Dewilde, W.J.1
Oirbans, T.2
Verheugt, F.W.3
-
28
-
-
84937636231
-
Evaluation of Dual Therapy with Dabigatran vs. Triple Therapy with Warfarin in Patients with AF that Undergo a PCI with Stenting (REDUAL-PCI): NCT02164864
-
ClinicalTrials.gov Web site [Updated September 15, 2015, Accessed October 5, 2015]
-
[28] Evaluation of Dual Therapy with Dabigatran vs. Triple Therapy with Warfarin in Patients with AF that Undergo a PCI with Stenting (REDUAL-PCI): NCT02164864. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT02164864 [Updated September 15, 2015, Accessed October 5, 2015].
-
-
-
-
29
-
-
84977643346
-
Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients with Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention (AUGUSTUS): NCT02415400
-
ClinicalTrials.gov Web site [Updated October 1, 2015, Accessed October 5, 2015]
-
[29] Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients with Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention (AUGUSTUS): NCT02415400. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT02415400?term=NCT02415400&rank=1 [Updated October 1, 2015, Accessed October 5, 2015].
-
-
-
-
30
-
-
84927573989
-
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)
-
[30] Gibson, C.M., Mehran, R., Bode, C., et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 169 (2015), 472–478.
-
(2015)
Am Heart J
, vol.169
, pp. 472-478
-
-
Gibson, C.M.1
Mehran, R.2
Bode, C.3
-
31
-
-
84891899155
-
GLOBAL LEADERS: a clinical study comparing two forms of anti-platelet therapy after stent implantation: NCT01813435
-
ClinicalTrials.gov Web site [Updated July 21, 2015, Accessed October 5, 2015]
-
[31] GLOBAL LEADERS: a clinical study comparing two forms of anti-platelet therapy after stent implantation: NCT01813435. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT01813435?term=NCT01813435&rank=1 [Updated July 21, 2015, Accessed October 5, 2015].
-
-
-
-
32
-
-
84977616984
-
Ticagrelor with Aspirin or Alone in High-risk Patients after Coronary Intervention (TWILIGHT): NCT02270242
-
ClinicalTrials.gov Web site [Updated September 8, 2015, Accessed October 5, 2015]
-
[32] Ticagrelor with Aspirin or Alone in High-risk Patients after Coronary Intervention (TWILIGHT): NCT02270242. ClinicalTrials.gov Web site https://clinicaltrials.gov/ct2/show/NCT02270242?term=nct02270242&rank=1 [Updated September 8, 2015, Accessed October 5, 2015].
-
-
-
-
33
-
-
84918772240
-
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
-
[33] Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
-
(2014)
N Engl J Med
, vol.371
, pp. 2155-2166
-
-
Mauri, L.1
Kereiakes, D.J.2
Yeh, R.W.3
-
34
-
-
84929884068
-
Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials
-
[34] Giustino, G., Baber, U., Sartori, S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 65 (2015), 1298–1310.
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 1298-1310
-
-
Giustino, G.1
Baber, U.2
Sartori, S.3
-
35
-
-
0037065502
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
-
[35] Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
-
(2002)
BMJ
, vol.324
, pp. 71-86
-
-
-
36
-
-
34248352504
-
Aspirin dose for the prevention of cardiovascular disease: a systematic review
-
[36] Campbell, C.L., Smyth, S., Montalescot, G., et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 (2007), 2018–2024.
-
(2007)
JAMA
, vol.297
, pp. 2018-2024
-
-
Campbell, C.L.1
Smyth, S.2
Montalescot, G.3
-
37
-
-
34247558672
-
Clinical end points in coronary stent trials: a case for standardized definitions
-
[37] Cutlip, D.E., Windecker, S., Mehran, R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
-
(2007)
Circulation
, vol.115
, pp. 2344-2351
-
-
Cutlip, D.E.1
Windecker, S.2
Mehran, R.3
-
38
-
-
85058721877
-
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET-AT study
-
[38] The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators, Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET-AT study. Am Heart J 159 (2010), 340–347.
-
(2010)
Am Heart J
, vol.159
, pp. 340-347
-
-
The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators,1
-
39
-
-
79959550517
-
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium
-
[39] Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123 (2011), 2736–2747.
-
(2011)
Circulation
, vol.123
, pp. 2736-2747
-
-
Mehran, R.1
Rao, S.V.2
Bhatt, D.L.3
-
40
-
-
84867577224
-
Third universal definition of myocardial infarction
-
[40] Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. Circulation 126 (2012), 2020–2035.
-
(2012)
Circulation
, vol.126
, pp. 2020-2035
-
-
Thygesen, K.1
Alpert, J.S.2
Jaffe, A.S.3
-
41
-
-
84937681428
-
2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trialsa report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards)
-
[41] Hicks, K.A., Tcheng, J.E., Bozkurt, B., et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trialsa report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Am Coll Cardiol 66 (2015), 403–469.
-
(2015)
J Am Coll Cardiol
, vol.66
, pp. 403-469
-
-
Hicks, K.A.1
Tcheng, J.E.2
Bozkurt, B.3
-
42
-
-
9244251971
-
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
-
[42] Schömig, A., Neumann, F.J., Kastrati, A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996), 1084–1089.
-
(1996)
N Engl J Med
, vol.334
, pp. 1084-1089
-
-
Schömig, A.1
Neumann, F.J.2
Kastrati, A.3
-
43
-
-
0031035542
-
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy
-
[43] Schömig, A., Neumann, F.J., Walter, H., et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 29 (1997), 28–34.
-
(1997)
J Am Coll Cardiol
, vol.29
, pp. 28-34
-
-
Schömig, A.1
Neumann, F.J.2
Walter, H.3
-
44
-
-
7844220998
-
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study
-
[44] Bertrand, M., Legrand, V., Boland, J., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 98 (1998), 1597–1603.
-
(1998)
Circulation
, vol.98
, pp. 1597-1603
-
-
Bertrand, M.1
Legrand, V.2
Boland, J.3
-
45
-
-
0032542028
-
Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
-
[45] Urban, P., Macaya, C., Rupprecht, H.J., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98 (1998), 2126–2132.
-
(1998)
Circulation
, vol.98
, pp. 2126-2132
-
-
Urban, P.1
Macaya, C.2
Rupprecht, H.J.3
-
46
-
-
84937622243
-
Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V coronary stent system trials
-
[pii:e001362, PMID: 25940520]
-
[46] Généreux, P., Rutledge, D.R., Palmerini, T., et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the Xience V coronary stent system trials. Circ Cardiovasc Interv, 8, 2015, 10.1161/CIRCINTERVENTIONS.114.001362 [pii:e001362, PMID: 25940520].
-
(2015)
Circ Cardiovasc Interv
, vol.8
-
-
Généreux, P.1
Rutledge, D.R.2
Palmerini, T.3
|